With 1.9 billion injections, this Jiangsu pharmaceutical company will be the first to be evaluated.

Pharmaceutical Network October 9th, recently, Jiangsu Yingke Bio according to the imitation of 4 categories of reported propofol / long-chain fat emulsion (receiving number CYHS1900274) registration status changed to "in the approval", is expected to be approved and the first review.
/long-chain fat emulsion is a fast and short-acting intravenous anesthetic with terminal sales of more than 1.9 billion yuan in public medical institutions in China in 2019.
propofol/long-chain fat emulsion is a fast- and short-acting intravenous anesthetic developed by Fessenyuscabi, which is widely used in peri-surgical anesthesia induction, anaesthetic maintenance, and sedation in ICU wards.
Currently the domestic market propofol / long-chain fat emulsion manufacturers only 4, Germany's two pharmaceutical companies Fessen Yuscabi, Belang approved for import, domestic 2 pharmaceutical companies Guangdong Jiabo Pharmaceuticals, Sichuan Guorui Pharmaceuticals approved imitation.
meters of intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal propofol / long chain fat emulsion sales of more than 1.9 billion yuan.
, Fessenyuscabi has a market share of 61.92 per cent, while Sichuan Guorui Pharmaceuticals has a market share of 19.31 per cent.
Propofol medium/ long-chain fat emulsion imitation 4 categories of review approval source: Minetrapnet one-click retrieval of the current propofol medium/long-chain fat emulsion did not have enterprises through the consistent evaluation.
Hengrui Pharmaceuticals, Hesco, Yangzijiang Pharmaceutical Group, Colum, Yunnan Longhai, Chongqing Pharmaceutical Friends and other 6 enterprises according to the imitation of 4 categories of submitted propofol medium / long chain fat milk injection application in the review;
.